RESUMEN
A liquid concentrate formulation of amitraz was clinically evaluated in 1721 canines showing demodicosis, by 25 veterinary investigators. The therapy was applied topically at 14-day intervals, and at a concentration of 250 ppm active drug in water. The miticide was efficacious and safe; approximately 99% of the canines showing localized or generalized demodicosis became clinically normal, and the side-effects recorded were minimal and transient. Approximately 3/4 of the patients were pure-bred animals and the majority were less than 1 year old. The clinical data support the conclusion that amitraz (liquid concentrate) is efficacious and safe for treating canine demodicosis.
Asunto(s)
Enfermedades de los Perros/tratamiento farmacológico , Insecticidas/uso terapéutico , Infestaciones por Ácaros/veterinaria , Toluidinas/uso terapéutico , Animales , Perros , Femenino , Insecticidas/administración & dosificación , Masculino , Infestaciones por Ácaros/tratamiento farmacológico , Seguridad , Toluidinas/administración & dosificaciónRESUMEN
A liquid concentrate formulation of amitraz (Mitaban: Upjohn) was used to topically treat 181 dogs with scabies, at an active drug level of 250 ppm, or 10.6 ml of concentrate in 2 gal water. After the dogs were clipped and bathed, the diluted medication was applied and allowed to dry on the animal. All treated dogs were clinically improved and 97.8% cured after a single treatment; 3 dogs required 2 treatments and 1 dog 3 treatments. Otodectes cynotis and Cheyletiella yasguri in several dogs were also cleared after 1 treatment. Mild, transient sedation occurred in 12.4% of treated dogs, with transient vomiting, increased appetite and diarrhea in less than 1%.